10-28 Abbott Laboratories : receives FDA approval for first and only device in the U.S. to treat leaks after heart valve replacement without additional surgery PU
10-27 Abbott Laboratories Shares Fall After Argus Downgrade MT
10-27 Argus Downgrades Abbott Laboratories to Hold From Buy MT
10-26 Abbott Laboratories Launches Oncodetect Molecular Residual Disease Test MT
10-26 Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment PR
10-26 Abbott Launches Whole-Genome Sequencing Oncodetect Molecular Residual Disease Test To Detect Traces Of Cancer During And After Treatment CI
10-23 Abbott Presents New Esmo Data Showing 30-Percent Absolute Improvement in Sensitivity with the Whole-Genome Sequencing Oncodetect Test in Colorectal Cancer CI
10-23 Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer PR
10-22 Abbott Laboratories' Q3 Somewhat a 'Mixed Bag' With Softened Outlook, Nutrition Spinoff, Oppenheimer Says MT
10-22 Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says MT
10-22 Jefferies & Co Adjusts Abbott Laboratories Price Target to $130 From $135 MT
10-22 RBC Trims Price Target on Abbott Laboratories to $125 From $130, Keeps Outperform Rating MT
10-22 Leerink Partners Adjusts Price Target on Abbott Laboratories to $106 From $109 MT
10-22 BTIG Adjusts Price Target on Abbott Laboratories to $125 From $134 MT
10-22 Wells Fargo Adjusts Price Target on Abbott Laboratories to $119 From $112 MT
10-22 JPMorgan Adjusts Price Target on Abbott Laboratories to $118 From $120 MT
10-22 TD Cowen Adjusts Price Target on Abbott Laboratories to $118 From $135 MT
10-21 Abbott Laboratories, Q3 2026 Earnings Call, Oct 21, 2026
10-21 Abbott to Carve Out Nutrition Business Into Independent Company -- 3rd Update DJ
10-21 Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
10-21 Abbott Announces Its Intention to Separate Its Nutrition Business into an Independent Publicly Traded Company CI
10-21 Abbott Laboratories Appoints Daniel Salvadori as Chief Executive Officer of the New Nutrition Company CI
10-21 Abbott to Carve Out Nutrition Business Into Independent Company -- 2nd Update DJ
10-21 Abbott Plans to Spin Off Its Nutrition Business Zonebourse
10-21 Abbott Labs to Carve Out Nutrition Business Into Independent Company -- Update DJ

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. ABT Stock
  4. News Abbott Laboratories